We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 4.03% | 4.90 | 4.77 | 5.00 | 4.94 | 4.6895 | 4.84 | 4,668,267 | 05:00:08 |
Details are as follows:
Abstract title: | Phase 3 PREPARE study: efficacy and safety of an RSV vaccine administered to pregnant women | ||
Session title: | PIDS/ESPID Joint Plenary Symposium – The future of vaccines (is now) | ||
Session code and track: | ST01; Science track | ||
Location: | Kocka Hall | ||
Date: | Tuesday, May 7 | ||
Time: | 10:30 a.m. ET |
The abstract for the presentation can be found here. In addition, the presentation will be live streamed. For more information, please visit the ESPID meeting’s website.
About ResVax™ and the Prepare Trial
ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In February 2019, Novavax announced top-line data from Prepare™, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
InvestorsNovavax, Inc.Erika Trahanir@novavax.com240-268-2000
WestwickeJohn Woolfordjohn.woolford@westwicke.com443-213-0506
MediaSam BrownAndrea Cohenandreacohen@sambrown.com917-209-7163
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions